Skip to content
Home » Epistra Epistra Co., Ltd. and MyOridge Co., Ltd. jointly succeeded in developing a culture medium for MSCs using AI

Epistra Epistra Co., Ltd. and MyOridge Co., Ltd. jointly succeeded in developing a culture medium for MSCs using AI

[Epistra] Epistra Co., Ltd. and MyOridge Co., Ltd. jointly succeeded in developing a culture medium for MSCs using AI

*View in browser* *Epistra*
Press release: May 8, 2024
**
Epistra Co., Ltd. and Myoridge Co., Ltd. jointly succeed in developing a culture medium for MSCs using AI
AI technology used this time
Epistra Co., Ltd. (Headquarters: Minato-ku, Tokyo, Representative Director and CEO: Ozawa
Yosuke (hereinafter referred to as “Epistra”) and MyOridge Co., Ltd. (Head office: Kyoto City, Kyoto Prefecture, President and CEO: Makita) Naohiro (hereinafter referred to as “MyOridge”) is jointly developing AI technology (Epistra).
We are pleased to announce that we have successfully developed a medium for mesenchymal stem cells (MSCs) by providing a culture medium development service using “Accelerate”.

In recent years, regenerative medicine and stem cell therapy have advanced in the medical field, bringing new possibilities to patient treatment. In particular, mesenchymal stem cells (MSCs) are expected to have therapeutic effects on a variety of diseases, and their promising application areas are expanding. However, there are still issues with the media used, and these issues range from cost, growth ability, and how to approach biological raw materials.

Epistra and Myoridge used cutting-edge AI algorithms to explore optimal culture conditions for their customers’ mesenchymal stem cells (MSCs). Epistra’s condition search AI algorithm (Epistra
By combining Myoridge’s medium development process, which combines technology for mass production of candidate media using our
proprietary medium composition database and high-throughput cell screening evaluation technology, we are able to successfully complete customer development in approximately four months. We succeeded in finding 75 types of media compositions that have better growth properties than the currently used media. All of the newly developed media are animal origin free (AOF) and do not contain factors derived from animals or humans. In the future, we plan to conduct long-term culture tests using the medium composition that was a hit.
This success demonstrates the strength of both companies’
technological capabilities and cooperative structure, and we will continue to work on further applications of cutting-edge technology.

* Overview of Epistra Co., Ltd. *
Company profile: Targeting companies conducting research and development in the life science field, such as pharmaceutical companies, we offer condition search AI “Epistra” that makes full use of independently developed AI technology.
We provide hands-on research support services using “Accelerate”. It has already been introduced in more than 40 cases, including major pharmaceutical companies, and in joint research with RIKEN, it succeeded in increasing the differentiation efficiency into retinal pigment epithelial cells by more than 80%, and it was selected by the international journal “eLife”. has been done.
Address: 2-2-15 Hamamatsucho, Minato-ku, Tokyo
URL: https://epistra.jp

* Overview of MyOridge Co., Ltd. *
Company Profile :
A startup company established based on research results from Kyoto University, we offer regeneration services such as media development services that utilize our own media component database and unique media screening technology, sales of iPS cell-derived cardiomyocytes, and manufacturing process development. We are developing services and other businesses for companies that develop medical products, biopharmaceuticals, and cultured foods.
Address: Room B5, Kyoto Institute of Technology, Main Building, 14 Yoshida Kawaramachi, Sakyo Ward, Kyoto City, Kyoto Prefecture URL: https://myoridge.co.jp
*About details about this release*
https://prtimes.jp/main/html/rd/p/000000007.000076234.html

*Download press release materials*
https://prtimes.jp/im/action.php?run=html&page=releaseimage&company_id=76234&release_id=7


Unsubscribe HTML email

Copyright © PR TIMES Corporation All Rights Reserved.

%d